Pfizer eyes submission after TTR readout

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality.

Pfizer has identified tafamidis, a small molecule

Read the full 397 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE